107 related articles for article (PubMed ID: 8748712)
1. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs.
Joseph MP; Maigret B; Scheraga HA
Int J Pept Protein Res; 1995 Dec; 46(6):514-26. PubMed ID: 8748712
[TBL] [Abstract][Full Text] [Related]
2. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
[TBL] [Abstract][Full Text] [Related]
3. Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation.
Nikiforovich GV; Kao JL; Plucinska K; Zhang WJ; Marshall GR
Biochemistry; 1994 Mar; 33(12):3591-8. PubMed ID: 8142357
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.
Wilkes BC; Masaro L; Schiller PW; Carpenter KA
J Med Chem; 2002 Sep; 45(20):4410-8. PubMed ID: 12238921
[TBL] [Abstract][Full Text] [Related]
5. Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.
Plucinska K; Kataoka T; Yodo M; Cody WL; He JX; Humblet C; Lu GH; Lunney E; Major TC; Panek RL
J Med Chem; 1993 Jun; 36(13):1902-13. PubMed ID: 8515427
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
Nikiforovich GV; Marshall GR
Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
[TBL] [Abstract][Full Text] [Related]
7. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
Tzakos AG; Gerothanassis IP; Troganis AN
Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
[TBL] [Abstract][Full Text] [Related]
8. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody.
Garcia KC; Ronco PM; Verroust PJ; Brünger AT; Amzel LM
Science; 1992 Jul; 257(5069):502-7. PubMed ID: 1636085
[TBL] [Abstract][Full Text] [Related]
10. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
[TBL] [Abstract][Full Text] [Related]
11. Conformational restriction of angiotensin II: cyclic analogues having high potency.
Spear KL; Brown MS; Reinhard EJ; McMahon EG; Olins GM; Palomo MA; Patton DR
J Med Chem; 1990 Jul; 33(7):1935-40. PubMed ID: 2362273
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the active conformation of angiotensin II: a comparison of AII and non-peptide AII antagonists.
Pierson ME; Freer RJ
Pept Res; 1992; 5(2):102-5. PubMed ID: 1581636
[TBL] [Abstract][Full Text] [Related]
13. Conformational properties of angiotensin II and its active and inactive TOAC-labeled analogs in the presence of micelles. Electron paramagnetic resonance, fluorescence, and circular dichroism studies.
Vieira RF; Casallanovo F; Marín N; Paiva AC; Schreier S; Nakaie CR
Biopolymers; 2009; 92(6):525-37. PubMed ID: 19728302
[TBL] [Abstract][Full Text] [Related]
14. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
[TBL] [Abstract][Full Text] [Related]
15. Conformational basis for the biological activity of TOAC-labeled angiotensin II and bradykinin: electron paramagnetic resonance, circular dichroism, and fluorescence studies.
Schreier S; Barbosa SR; Casallanovo F; Vieira Rde F; Cilli EM; Paiva AC; Nakaie CR
Biopolymers; 2004 Aug; 74(5):389-402. PubMed ID: 15222018
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II binding sites in frog kidney and adrenal.
Kloas W; Hanke W
Peptides; 1992; 13(2):349-54. PubMed ID: 1409013
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin and angiotensin II analogs containing a conformationally constrained proline analog.
Juvvadi P; Dooley DJ; Humblet CC; Lu GH; Lunney EA; Panek RL; Skeean R; Marshall GR
Int J Pept Protein Res; 1992; 40(3-4):163-70. PubMed ID: 1335995
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the solution structures of angiotensin I & II. Implication for structure-function relationship.
Spyroulias GA; Nikolakopoulou P; Tzakos A; Gerothanassis IP; Magafa V; Manessi-Zoupa E; Cordopatis P
Eur J Biochem; 2003 May; 270(10):2163-73. PubMed ID: 12752436
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells.
Webb ML; Liu EC; Cohen RB; Hedberg A; Bogosian EA; Monshizadegan H; Molloy C; Serafino R; Moreland S; Murphy TJ
Peptides; 1992; 13(3):499-508. PubMed ID: 1326103
[TBL] [Abstract][Full Text] [Related]
20. Biological and conformational evaluation of angiotensin II lactam bridge containing analogues.
Oliveira VX; Fázio MA; Silva AF; Campana PT; Pesquero JB; Santos EL; Costa-Neto CM; Miranda A
Regul Pept; 2011 Dec; 172(1-3):1-7. PubMed ID: 21787808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
